Clofibric acid: A potential therapeutic agent in AML and MDS

British Journal of Haematology

Volumn 105, Issue 2, 1999, Pages 448-451

  Fenton, S L ^a   Drayson, M T ^a   Hewison, M ^a   Vickers, E ^a   Brown, G ^a   Bunce, C M ^b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

All trans retinoic acid; AML; Clofibric acid; Differentiation therapy; MDS

Indexed keywords

CALCITRIOL; CLOFIBRIC ACID; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL STRAIN HL 60; DRUG TOLERABILITY; HUMAN; HUMAN CELL; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 0032901007     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.1999.01355.x     Document Type: Article

References (12)

1. Asou, H., Verbeek, T., Kubota, T., Elstner E., Koshizuka, K. & Koeffler, H.P. (1997) Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor γ (PPARγ) and retinoids. Blood, 90, (Suppl. 2), 2846.
2. Anonymous (1984) WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principle Investigators. Lancet, ii, 600-604.
3. Bunce, CM., Mountford, J.C., French, P.J., Mole, D.J., Durham, J., Michell, R.H. & Brown, G. (1996) Potentiation of myeloid differentiation by anti-inflammatory agents, by steroids and by retinoic acid involves a single intracellular target probably an enzyme of the aldoketoreductase family. Biochimica et Biophysica Acta, 1311, 189-198.
4. Evans, R.M. (1988) The steroid and thyroid receptor superfamily. Science, 240, 889-895.
5. Forman, B.M., Chen, J. & Evans, R.M. (1997) Hypolidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and γ. Proceedings of the National Academy of Sciences of the United States of America, 94, 4312-4317.
6. Gitlin, N., Julie, N.L., Spurr, C.L., Lim, K.N. & Juarbe, H.M. (1998) Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Annals of Internal Medicine, 129, 36-38.
7. Kizaki, M., Ikeda, Y., Tanosaki, R., Nakajima, H., Morikawa, M., Sakashita, A. & Koeffler, H.P. (1993) Effects of novel retinoic acid compound, 9-cis retinoic acid, on proliferation differentiation, and expression of retinoic acid receptor-α RNA by HL60 cells. Blood, 82, 3592-3599.
8. Morosetti, R. & Koeffler, H.P. (1996) Differentiation therapy in myelodysplastic syndromes. Seminars in Hematology, 33, 236-245.
9. Neuschwander-Tetri, B.A., Isley, W.L., Oki, J.C., Ramrakhiani, S., Quiason, S.G., Phillips, N.J. & Brunt, E.M. (1998) Troglitazone-induced hepatic failure leading to liver transplantation: a case report. Annals of Internal Medicine, 129, 38-41.
10. Nilsson, A., Farants, A.K., Nesland, J.M., Finstad, H.S. & Pederson, J.L. (1995) Potentiating effects of clofibric acid on the differentiation of HL-60 human promyelocytic leukemia cells induced by retinoids. European Journal of Cell Biology, 67, 379-385.
11. Roa, M.S. & Reddy, J.K. (1996) Hepatocarcinogenesis of peroxisome proliferators. Annals of the New York Academy of Sciences, 804, 573-587.
12. Taylor, P.R., Reid, M.M., Stark, A.N., Brown, N, Hamilton, P.J. & Proctor, S.J. (1995) De novo acute myeloid leukaemia in patients over 55 years old: a population-based study of incidence, treatment and outcome. Northern Region haematology group. Leukemia, 9, 231-237.